Browse by category

Innovent’s Mazdutide 9mg accepted for review by China’s NMPA

Innovent Biologics’ supplementary application for the 9 mg dosage of mazdutide, an innovative glucagon (GCG)/ glucagon-like peptide-1 (GLP-1) dual receptor agonist, for the long-term weight management in adults with moderate to severe obesity has been accepted for review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). This application of mazdutide 9 mg aims to address a pressing unmet clinical need in China by offering a hig

Metabolic bariatric surgery associated with an improvement in psoriasis outcomes

1 hour ago

Postoperative complications of medical tourism may cost NHS up to £20,000 per patient

2 hours ago

First patients randomised in KaiNETIC Global Phase 3 Clinical Program of ribupatide

1 day ago

Browse by category

Innovent’s Mazdutide 9mg accepted for review by China’s NMPA

Browse by tag

Metabolic bariatric surgery associated with an improvement in psoriasis outcomes

Postoperative complications of medical tourism may cost NHS up to £20,000 per patient

First patients randomised in KaiNETIC Global Phase 3 Clinical Program of ribupatide

Back to Top